This is a PDF-only article. The first page of the PDF of this article appears above.
In this issue
Radioimmunotherapy of Medullary Thyroid Cancer with Iodine-131-Labeled Anti-CEA Antibodies
Jump to section
Related Articles
Cited By...
- SPECT- and Fluorescence Image-Guided Surgery Using a Dual-Labeled Carcinoembryonic Antigen-Targeting Antibody
- Phase II Trial of Anticarcinoembryonic Antigen Pretargeted Radioimmunotherapy in Progressive Metastatic Medullary Thyroid Carcinoma: Biomarker Response and Survival Improvement
- A transplantable human medullary thyroid carcinoma as a model for RET tyrosine kinase-driven tumorigenesis
- Enhanced Antitumor Activity of Combined Pretargeted Radioimmunotherapy and Paclitaxel in Medullary Thyroid Cancer Xenograft
- A Phase I Radioimmunotherapy Trial Evaluating 90Yttrium-labeled Anti-Carcinoembryonic Antigen (CEA) Chimeric T84.66 in Patients with Metastatic CEA-producing Malignancies
- Successful Surgical Removal of Occult Metastases of Medullary Thyroid Carcinoma Recurrences with the Help of Immunoscintigraphy and Radioimmunoguided Surgery